[1]张腾旭 李子伟 徐颖 徐超群 王好 芮涛.线粒体自噬在糖尿病心肌病中的研究进展[J].心血管病学进展,2025,(8):716.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.011]
 ZHANG Tengxu,LI Ziwei,XU Ying,et al.Advancements in the Study of Mitophagy in Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2025,(8):716.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.011]
点击复制

线粒体自噬在糖尿病心肌病中的研究进展()

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2025年8期
页码:
716
栏目:
综述
出版日期:
2025-08-25

文章信息/Info

Title:
Advancements in the Study of Mitophagy in Diabetic Cardiomyopathy
作者:
张腾旭 李子伟 徐颖 徐超群 王好 芮涛
(江苏大学附属人民医院,江苏 镇江 212002)
Author(s):
ZHANG TengxuLI ZiweiXU YingXU ChaoqunWANG HaoRui Tao
(People’s Hospital Affiliated to Jiangsu University,Zhenjiang 212002,Jiangsu,China)
关键词:
糖尿病心肌病线粒体自噬线粒体功能障碍氧化应激PINK1/Parkin通路
Keywords:
Diabetic cardiomyopathyMitophagyMitochondrial dysfunctionOxidative stressPINK1/Parkin pathway
DOI:
10.16806/j.cnki.issn.1004-3934.2024.08.011
摘要:
心血管疾病是导致糖尿病患者死亡的重要原因。糖尿病心肌病(DCM)的特征是在不存在冠状动脉疾病、高血压及其他心脏疾病的情况下,糖尿病引发心肌肥厚、纤维化,致使心肌舒张功能受损,并逐渐发展为心肌收缩功能下降。线粒体自噬作为细胞内特异性清除受损线粒体的关键过程,对维持细胞功能的健康状态起着重要的作用。近年来的研究表明,线粒体自噬在DCM的发病机制中占据关键地位。在糖尿病中,氧化应激、晚期糖基化终末产物积累等因素可诱导心肌细胞内线粒体自噬的过度激活或抑制,进而引发线粒体功能障碍,最终导致心肌功能受损。PINK1/Parkin通路是泛素依赖途径中调控线粒体自噬的重要机制,但在糖尿病环境中,该通路的异常激活可能会导致不同程度的心肌损害。此外,Bnip3、FUNDC1等分子介导的非泛素依赖性线粒体自噬通路,也在DCM的病理变化中发挥着重要作用。现深入剖析了DCM的病理生理特点,详细阐述线粒体自噬在DCM中的作用机制,并对线粒体自噬的途径及其功能进行了全面综述。最后,探讨了通过调节线粒体自噬来治疗DCM的重要治疗策略,为DCM的临床治疗提供新的思路和方向。
Abstract:
Cardiovascular disease is a major cause of death in people with diabetes. Diabetic cardiomyopathy (DCM) involves heart muscle enlargement and fibrosis due to diabetes,without other heart conditions,leading to impaired heart function. Mitophagy,the process of removing damaged mitochondria,is crucial for cell health and plays a key role in DCM. In diabetes,oxidative stress and other factors can disrupt mitophagy in heart cells,causing mitochondrial dysfunction and weakened heart function. The PINK1/Parkin pathway is key for mitophagy regulation via ubiquitin,but its abnormal activation can cause myocardial damage in diabetes. Non-ubiquitin mitophagy,involving Bnip3 and FUNDC1,also contributes to diabetic cardiomyopathy. This article explores the pathophysiology of diabetic cardiomyopathy,details mitophagy mechanisms,reviews related pathways,and suggests regulating mitophagy as a potential treatment strategy,providing new clinical insights

参考文献/References:

[1] Rubler S,Dlugash J,Yuceoglu YZ,et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis[J]. Am J Cardiol,1972,30(6):595-602.

[2] Nakamura K,Miyoshi T,Yoshida M,et al. Pathophysiology and treatment of diabetic cardiomyopathy and heart failure in patients with diabetes mellitus[J]. Int J Mol Sci,2022,23(7):3587.

[3] Yan M,Li Y,Luo Q,et al. Mitochondrial damage and activation of the cytosolic DNA sensor cGAS-STING pathway lead to cardiac pyroptosis and hypertrophy in diabetic cardiomyopathy mice[J]. Cell Death Discov,2022,8(1):258.

[4] Frangogiannis NG. Cardiac fibrosis[J]. Cardiovasc Res,2021,117(6):1450-1488.

[5] Atici AE,Crother TR,Noval Rivas M. Mitochondrial quality control in health and cardiovascular diseases[J]. Front Cell Dev Biol,2023,11:1290046.

[6] Prandi FR,Evangelista I,Sergi D,et al. Mechanisms of cardiac dysfunction in diabetic cardiomyopathy:molecular abnormalities and phenotypical variants[J]. Heart Fail Rev,2023,28(3):597-606.

[7] Lin J,Duan J,Wang Q,et al. Mitochondrial dynamics and mitophagy in cardiometabolic disease[J]. Front Cardiovasc Med,2022,9:917135.

[8] Jin L,Geng L,Ying L,et al. FGF21-sirtuin 3 axis confers the protective effects of exercise against diabetic cardiomyopathy by governing mitochondrial integrity[J]. Circulation,2022,146(20):1537-1557.

[9] Huo S,Wang Q,Shi W,et al. ATF3/SPI1/SLC31A1 signaling promotes cuproptosis induced by advanced glycosylation end products in diabetic myocardial injury[J]. Int J Mol Sci,2023,24(2):1667.

[10] Ke J,Pan J,Lin H,et al. Diabetic cardiomyopathy:a brief summary on lipid toxicity[J]. ESC Heart Fail,2023,10(2):776-790.

[11] Klionsky DJ,Abeliovich H,Agostinis P,et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes[J]. Autophagy,2008,4(2):151-175.

[12] Lu Y,Li Z,Zhang S,et al. Cellular mitophagy:mechanism,roles in diseases and small molecule pharmacological regulation[J]. Theranostics,2023,13(2):736-766.

[13] Zhang M,Sui W,Xing Y,et al. Angiotensin IV attenuates diabetic cardiomyopathy via suppressing FoxO1-induced excessive autophagy,apoptosis and fibrosis[J]. Theranostics,2021,11(18):8624-8639.

[14] Wang N,Zhu P,Huang R,et al. PINK1:the guard of mitochondria[J]. Life Sci,2020,259:118247.

[15] Wilhelm LP,Zapata-Mu?oz J,Villarejo-Zori B,et al. BNIP3L/NIX regulates both mitophagy and pexophagy[J]. EMBO J,2022,41(24):e111115.

[16] Nguyen-Dien GT,Kozul KL,Cui Y,et al. FBXL4 suppresses mitophagy by restricting the accumulation of NIX and BNIP3 mitophagy receptors[J]. EMBO J,2023,42(13):e112767.

[17] Sun Y,Zhou S,Guo H,et al. Protective effects of sulforaphane on type 2 diabetes-induced cardiomyopathy via AMPK-mediated activation of lipid metabolic pathways and NRF2 function[J]. Metabolism,2020,102:154002.

[18] Han YC,Tang SQ,Liu YT,et al. AMPK agonist alleviate renal tubulointerstitial fibrosis via activating mitophagy in high fat and streptozotocin induced diabetic mice[J]. Cell Death Dis,2021,12(10):925.

[19] Drake JC,Wilson RJ,Laker RC,et al. Mitochondria-localized AMPK responds to local energetics and contributes to exercise and energetic stress-induced mitophagy[J]. Proc Natl Acad Sci U S A,2021,118(37):e2025932118.

[20] Parmar UM,Jalgaonkar MP,Kansara AJ,et al. Emerging links between FOXOs and diabetic complications[J]. Eur J Pharmacol,2023,960:176089.

[21] Yao J,Wang J,Xu Y,et al. CDK9 inhibition blocks the initiation of PINK1-PRKN-mediated mitophagy by regulating the SIRT1-FOXO3-BNIP3 axis and enhances the therapeutic effects involving mitochondrial dysfunction in hepatocellular carcinoma[J]. Autophagy,2022,18(8):1879-1897.

[22] Salin Raj P,Nair A,Preetha Rani MR,et al. Ferulic acid attenuates high glucose-induced MAM alterations via PACS2/IP3R2/FUNDC1/VDAC1 pathway activating proapoptotic proteins and ameliorates cardiomyopathy in diabetic rats[J]. Int J Cardiol,2023,372:101-109.

[23] Bi Y,Liu S,Qin X,et al. FUNDC1 interacts with GPx4 to govern hepatic ferroptosis and fibrotic injury through a mitophagy-dependent manner[J]. J Adv Res,2024,55:45-60.

[24] Chu C,Wang X,Yang C,et al. Neutrophil extracellular traps drive intestinal microvascular endothelial ferroptosis by impairing Fundc1-dependent mitophagy[J]. Redox Biol,2023,67:102906.

[25] Peng H,Fu S,Wang S,et al. Ablation of FUNDC1-dependent mitophagy renders myocardium resistant to paraquat-induced ferroptosis and contractile dysfunction[J]. Biochim Biophys Acta Mol Basis Dis,2022,1868(9):166448.

[26] Li FJ,Hu H,Wu L,et al. Ablation of mitophagy receptor FUNDC1 accentuates septic cardiomyopathy through ACSL4-dependent regulation of ferroptosis and mitochondrial integrity[J]. Free Radic Biol Med,2024,225:75-86.

[27] Pei Z,Liu Y,Liu S,et al. FUNDC1 insufficiency sensitizes high fat diet intake-induced cardiac remodeling and contractile anomaly through ACSL4-mediated ferroptosis[J]. Metabolism,2021,122:154840.

[28] Zahid MA,Abdelsalam SS,Raiq H,et al. Sestrin2 as a protective shield against cardiovascular disease[J]. Int J Mol Sci,2023,24(5):4880.

[29] Song S,Shi C,Bian Y,et al. Sestrin2 remedies podocyte injury via orchestrating TSP-1/TGF-β1/Smad3 axis in diabetic kidney disease[J]. Cell Death Dis,2022,13(7):663.

[30] Watany MM,El-Horany HE,Elhosary MM,et al. Clinical application of RUBCN/SESN2 mediated inhibition of autophagy as biomarkers of diabetic kidney disease[J]. Mol Med,2022,28(1):147.

[31] Ding X,Zhao H,Qiao C. Icariin protects podocytes from NLRP3 activation by Sesn2-induced mitophagy through the Keap1-Nrf2/HO-1 axis in diabetic nephropathy[J]. Phytomedicine,2022,99:154005.

[32] Xiao T,Zhao H,Wang Y,et al. Shionone inhibits glomerular fibirosis by suppressing NLRP3 related inflammasome though SESN2-NRF2/ HO-1 pathway[J]. Diabetes Metab J,2025,49(1):34-48.

[33] Li S,Liu M,Chen J,et al. L-carnitine alleviates cardiac microvascular dysfunction in diabetic cardiomyopathy by enhancing PINK1-Parkin-dependent mitophagy through the CPT1a-PHB2-PARL pathways[J]. Acta Physiol (Oxf),2023,238(3):e13975.

[34] Li Y,Chen H,Xie X,et al. PINK1-mediated mitophagy promotes oxidative phosphorylation and redox homeostasis to induce drug-tolerant persister cancer cells[J]. Cancer Res,2023,83(3):398-413.

[35] Yin K,Lee J,Liu Z,et al. Mitophagy protein PINK1 suppresses colon tumor growth by metabolic reprogramming via p53 activation and reducing acetyl-CoA production[J]. Cell Death Differ,2021,28(8):2421-2435.

[36] Boshchenko AA,Maslov LN,Mukhomedzyanov AV,et al. Peptides are cardioprotective drugs of the future:the receptor and signaling mechanisms of the cardioprotective effect of glucagon-like peptide-1 receptor agonists[J]. Int J Mol Sci,2024,25(9):4900.

[37] Wang J,Yang K,Liu C,et al. H3 relaxin ameliorates mitochondrial quality control and apoptosis in cardiomyocytes of type 2 diabetic rats via activation of the AMPK pathway[J]. Int Immunopharmacol,2025,144:113664.

[38] Tan X,Chen YF,Zou SY,et al. ALDH2 attenuates ischemia and reperfusion injury through regulation of mitochondrial fusion and fission by PI3K/AKT/mTOR pathway in diabetic cardiomyopathy[J]. Free Radic Biol Med,2023,195:219-230.

[39] Yu LM,Dong X,Xue XD,et al. Melatonin attenuates diabetic cardiomyopathy and reduces myocardial vulnerability to ischemia-reperfusion injury by improving mitochondrial quality control:Role of SIRT6[J]. J Pineal Res,2021,70(1):e12698.

[40] Arab HH,Al-Shorbagy MY,Saad MA. Activation of autophagy and suppression of apoptosis by dapagliflozin attenuates experimental inflammatory bowel disease in rats:targeting AMPK/mTOR,HMGB1/RAGE and Nrf2/HO-1 pathways[J]. Chem Biol Interact,2021,335:109368.

[41] Chen Z,Li S,Liu M,et al. Nicorandil alleviates cardiac microvascular ferroptosis in diabetic cardiomyopathy:role of the mitochondria-localized AMPK-Parkin-ACSL4 signaling pathway[J]. Pharmacol Res,2024,200:107057.

相似文献/References:

[1]王静娜,侯瑞田,史亦男,等.糖尿病心肌病发病机制及病理改变研究进展[J].心血管病学进展,2016,(4):412.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.022]
 WANG Jingna,HOU Ruitian,SHI Yinan,et al.Research Progress on Pathogenesis and Pathological Changes of Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(8):412.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.022]
[2]杨沫,姜文锡.线粒体功能异常在糖尿病心肌病发病机制中的作用[J].心血管病学进展,2015,(6):731.[doi:10.3969/j.issn.1004-3934.2015.06.019]
 YANG Mo,JIANG Wenxi.Mitochondrial Dysfunction of Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2015,(8):731.[doi:10.3969/j.issn.1004-3934.2015.06.019]
[3]朱月红,戴启明.糖尿病心肌病的内质网病变机制及干预[J].心血管病学进展,2015,(6):738.[doi:10.3969/j.issn.1004-3934.2015.06.021]
 ZHU Yuehong,DAI Qiming.Advance of Mechanism and Intervention of Endoplasmic Reticulum in Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2015,(8):738.[doi:10.3969/j.issn.1004-3934.2015.06.021]
[4]位晨晨,钟明.糖尿病心肌病的发病机制[J].心血管病学进展,2020,(2):135.[doi:10.16806/j.cnki.issn.1004-3934.20.02.009]
 WEI Chenchen,ZHONG Ming.Pathogenesis of Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(8):135.[doi:10.16806/j.cnki.issn.1004-3934.20.02.009]
[5]付辉,黄鹤.线粒体功能障碍在心血管疾病中的作用[J].心血管病学进展,2020,(3):306.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.022]
 FU Hui,HUANG He.Role of Mitochondrial Dysfunction in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(8):306.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.022]
[6]武韧 常贵全 孙凤起 李鸿珠.硫化氢对糖尿病心肌病的保护作用[J].心血管病学进展,2021,(1):52.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
 WU Ren,CHANG Guiquan,SUN Fengqi,et al.Protective Effect of Hydrogen Sulfide in Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(8):52.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
[7]宋元秀 崔鸣.线粒体动力学异常与相关心血管疾病[J].心血管病学进展,2021,(2):162.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
 SONG Yuanxiu,CUI Ming.Correlation Between Mitochondrial Dynamics and Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2021,(8):162.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
[8]马韵之 李剑 周鹏.糖尿病心肌病血清生物标志物研究进展[J].心血管病学进展,2021,(5):392.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.002]
 Serum Biomarkers of Diabetic Cardiomyopathy.[J].Advances in Cardiovascular Diseases,2021,(8):392.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.002]
[9]李开 饶莉.线粒体自噬的分子生物学过程及其在心脏疾病中的作用[J].心血管病学进展,2022,(3):222.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
 LI Kai,RAO Li.Molecular Biological Process of Mitophagy and Its Role in Heart Diseases[J].Advances in Cardiovascular Diseases,2022,(8):222.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[10]李艳鹏 马依彤.糖尿病心肌病治疗策略的研究进展[J].心血管病学进展,2022,(9):795.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.007]
 LI Yanpeng,MA Yitong.Treatment Strategies for Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2022,(8):795.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.007]

更新日期/Last Update: 2025-11-11